Skip to main content
Premium Trial:

Request an Annual Quote

Jan Mous

Premium

Jan Mous, former CSO of Lion Bioscience, has been appointed CEO of genomic-based target discovery firm IntegraGen. Mous will also serve as chairman of the company’s board of directors. Mous left his post as CSO of Lion in January, after holding the position for three years. Prior to that, he spent fifteen years at Roche (Basel, Switzerland), where he was global head of genomics technology and managing director of the genetics/genomics technology platform.

Filed under

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.